Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

NCT00066625 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

NIH

Sponsor class

Stopped Administratively complete.

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: oxaliplatin
DRUG: bortezomib
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)